164 related articles for article (PubMed ID: 31083581)
1. The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40.
Caisova V; Li L; Gupta G; Jochmanova I; Jha A; Uher O; Huynh TT; Miettinen M; Pang Y; Abunimer L; Niu G; Chen X; Ghayee HK; Taïeb D; Zhuang Z; Zenka J; Pacak K
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31083581
[TBL] [Abstract][Full Text] [Related]
2. Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.
Uher O; Huynh TT; Zhu B; Horn LA; Caisova V; Hadrava Vanova K; Medina R; Wang H; Palena C; Chmelar J; Zhuang Z; Zenka J; Pacak K
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439097
[TBL] [Abstract][Full Text] [Related]
3. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Uher O; Caisova V; Padoukova L; Kvardova K; Masakova K; Lencova R; Frejlachova A; Skalickova M; Venhauerova A; Chlastakova A; Hansen P; Chmelar J; Kopecky J; Zhuang Z; Pacak K; Zenka J
Cancer Immunol Immunother; 2021 Nov; 70(11):3303-3312. PubMed ID: 33855601
[TBL] [Abstract][Full Text] [Related]
4. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
[TBL] [Abstract][Full Text] [Related]
5. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
[TBL] [Abstract][Full Text] [Related]
6. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis.
Caisová V; Uher O; Nedbalová P; Jochmanová I; Kvardová K; Masáková K; Krejčová G; Paďouková L; Chmelař J; Kopecký J; Ženka J
Int Immunopharmacol; 2018 Jun; 59():86-96. PubMed ID: 29635103
[TBL] [Abstract][Full Text] [Related]
7. Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Medina R; Wang H; Caisová V; Cui J; Indig IH; Uher O; Ye J; Nwankwo A; Sanchez V; Wu T; Nduom E; Heiss J; Gilbert MR; Terabe M; Ho W; Zenka J; Pacak K; Zhuang Z
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 33709018
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.
Uher O; Hadrava Vanova K; Lencova R; Frejlachova A; Wang H; Zhuang Z; Zenka J; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1030412. PubMed ID: 37342258
[TBL] [Abstract][Full Text] [Related]
9. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Diagnostic, and Treatment Characteristics of
Jha A; de Luna K; Balili CA; Millo C; Paraiso CA; Ling A; Gonzales MK; Viana B; Alrezk R; Adams KT; Tena I; Chen A; Neuzil J; Raygada M; Kebebew E; Taieb D; O'Dorisio MS; O'Dorisio T; Civelek AC; Stratakis CA; Mercado-Asis L; Pacak K
Front Oncol; 2019; 9():53. PubMed ID: 30854332
[No Abstract] [Full Text] [Related]
11. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
12. Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
Caisová V; Vieru A; Kumžáková Z; Glaserová S; Husníková H; Vácová N; Krejčová G; Paďouková L; Jochmanová I; Wolf KI; Chmelař J; Kopecký J; Ženka J
BMC Cancer; 2016 Dec; 16(1):940. PubMed ID: 27927165
[TBL] [Abstract][Full Text] [Related]
13. The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
Frejlachova A; Lencova R; Venhauerova A; Skalickova M; Uher O; Caisova V; Majer P; Tenora L; Hansen P; Chmelar J; Kopecky J; Zhuang Z; Pacak K; Zenka J
Int Immunopharmacol; 2023 May; 118():110150. PubMed ID: 37030115
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
[TBL] [Abstract][Full Text] [Related]
16. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?
Grouzmann E; Tschopp O; Triponez F; Matter M; Bilz S; Brändle M; Drechser T; Sigrist S; Zulewski H; Henzen C; Fischli S; Abid K
PLoS One; 2015; 10(5):e0125426. PubMed ID: 25946206
[TBL] [Abstract][Full Text] [Related]
17. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
18. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1.
Gruber LM; Erickson D; Babovic-Vuksanovic D; Thompson GB; Young WF; Bancos I
Clin Endocrinol (Oxf); 2017 Jan; 86(1):141-149. PubMed ID: 27460956
[TBL] [Abstract][Full Text] [Related]
19. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
[TBL] [Abstract][Full Text] [Related]
20. Primary tumour resection for synchronously metastatic phaeochromocytoma and paraganglioma: A population-based study.
Wu K; Zhou C; Liu Z; Lu Y; Li X
Clin Endocrinol (Oxf); 2020 Dec; ():. PubMed ID: 33349934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
